[{"id":"fd14e8af-6cb8-4bd3-b1fb-c8845a7616b6","acronym":"SAFE-T-HBV","url":"https://clinicaltrials.gov/study/NCT04745403","created_at":"2022-07-02T01:54:42.621Z","updated_at":"2024-07-02T16:35:28.875Z","phase":"Phase 1","brief_title":"Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)","source_id_and_acronym":"NCT04745403 - SAFE-T-HBV","lead_sponsor":"Lion TCR Pte. Ltd.","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24:02 • HLA-A*24","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24:02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LioCyx-M"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 05/20/2022","start_date":" 05/20/2022","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2023-11-17"},{"id":"30e6b0d2-9ae8-42e8-950a-d7ffc20b493b","acronym":"WIZARD201G","url":"https://clinicaltrials.gov/study/NCT03149003","created_at":"2021-06-30T14:53:13.951Z","updated_at":"2024-07-02T16:35:29.166Z","phase":"Phase 3","brief_title":"A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy","source_id_and_acronym":"NCT03149003 - WIZARD201G","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" MGMT • HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24:02 • HLA-A*24","tags":["MGMT • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24:02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • adegramotide/nelatimotide (DSP-7888)"],"overall_status":"Completed","enrollment":" Enrollment 221","initiation":"Initiation: 12/08/2017","start_date":" 12/08/2017","primary_txt":" Primary completion: 08/30/2021","primary_completion_date":" 08/30/2021","study_txt":" Completion: 08/30/2021","study_completion_date":" 08/30/2021","last_update_posted":"2023-11-15"}]